Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Authors:
- Aditya BardiaABAditya Bardia
- Javier CortésJavier Cortés
- François-Clément BidardFBFrançois-Clément Bidard
- Patrick NevenPatrick Neven
- José Garcia-SáenzJGJosé Garcia-Sáenz
- Phillipe AftimosPAPhillipe Aftimos
- Joyce O’sHaughnessyJOJoyce O’sHaughnessy
- Janice LuJLJanice Lu
- Giulia ToniniGTGiulia Tonini
- Simona ScartoniSSSimona Scartoni
- Alessandro PaoliAPAlessandro Paoli
- Monica BinaschiMBMonica Binaschi
Top Cited Papers
Open Access
- 1 August 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4299-4309
Abstract
Purpose: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months. Patients and Methods: EMERALD, an open-label phase III trial, randomly assigned patients with ER+, HER2− metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing. Results: In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 (<3 metastatic sites), 10.8 versus 1.8 (≥3 metastatic sites), 5.5 versus 1.9 (PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 (ESR1D538G-mutated tumors), and 9.0 versus 1.9 (ESR1Y537S/N-mutated tumors). Subgroup safety was consistent with the overall population. Conclusions: The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2−, ESR1-mutated tumors.Keywords
All Related Versions
This publication has 62 references indexed in Scilit:
- The prognostic value of PI3K mutational status in breast cancer: A meta‐analysisJournal of Cellular Biochemistry, 2018
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of Clinical Oncology, 2017
- Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2016
- TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic RelevanceClinical Cancer Research, 2014
- Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 2014
- The search for ESR1 mutations in breast cancerNature Genetics, 2013
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009